Receive FREE, personalized advice on your organization's mission-critical
challenges from experts in a variety of fields.
For the second year, Partnering for Cures will offer free, private, one-on-one meetings with leading experts from across the medical research field. The Expert Consultant Track allows registered conference participants to find specialists with a wide range of expertise through the partnering system, and request one-on-one sessions on a variety of commonly faced issues.
Experts will provide issue analysis and tailored feedback based on participants'
specific needs and challenges, and will be available through the EBD partnering
system. A list of topics and current list of experts are below.
| How to schedule a meeting via the partnering system |
Once in the partnering system, you can search for the expert consultants via the search tool by:
- Using keywords "Expert Consultant"
- Searching first and last name
Once you have found the consultant that you want to meet with at the conference - follow the prompts to send a meeting request. The expert consultant will respond to your request and then you can find a mutually agreeable time during Partnering for Cures to schedule your session.
Note: All registered attendees should have received notification
of how to activate your partnering account and create your profile. |
|
These consultations will address strategic and business model issues including establishing planning guidelines and timelines, conducting strategic analysis and organizational assessments, setting or changing strategic direction, refining goals and methods, approaching collaborations (with both partners and funders), and mapping/measuring success.
- L. Russell (Rusty) Bromley - Principal, TRAC Consulting
- Katie Hood, M.B.A. - Former Chief Executive Officer, Michael J. Fox Foundation for Parkinson's Research
- Marie Schiller - Partner, Health Advances
These consultations will address various methods for formalizing and carrying out cross-sector partnerships as efficiently and effectively as possible. They will cover issues such as intellectual property, data sharing, and conflicts of interest to ensure that the proper legal and structural agreements/policies/processes are in place for successful collaborations.
- Carol Greve-Philips - Former Vice President, Corporate
Development, Genzyme Corp.
- David Lubitz, J.D. - Attorney, Schaner & Lubitz
- John McKew, Ph.D. - Chief, Therapeutic Development Branch, National Center for Translational Therapeutics, National Institutes of Health
- Teri Melese, Ph.D. - Associate Professor of Medicine and Director of Research Technologies and Alliances, School of Medicine, Dean's Office, University of California, San Francisco
- Eric Nelson, Ph.D. - Chief Executive Officer, NCE Biotech Consulting
- Mark Scheideler, Ph.D. - Founder, HumanFirst Therapeutics, LLC
These consultations will address the strategic acquisition and allocation of philanthropic capital. Consultants will come from both the foundation and investor perspectives, and will provide guidance on issues such as attracting investors, understanding/evaluating philanthropic investment objectives, building a high-impact medical portfolio, resource-building, etc.
- Eric Kessler, M.B.A. - Principal and Managing Director, Arabella Philanthropic Investment Advisors
- Melanie Schnoll Begun, J.D. - Managing Director and Head of Philanthropic Services, Morgan Stanley Smith Barney
These consultations will address strategies for building visibility and credibility with collaborators and media. They will examine how to evaluate and pursue promotional and thought leadership opportunities, how to develop a compelling and differentiating narrative about your organization/project, and where/how to engage key opinion leaders and potential collaborators.
- Karen Bergman - Founder and Partner, BCC Partners LLC
- Alex Brownstein - Senior Vice President, DJE Science
- Mark Krueger, M.P.H. - President, Mark Krueger & Associates, Inc.
- Barbara Lavery - President, Zoomedia, Inc.
- Maureen Suda, M.S. - Principal, Suda Communications LLC
These consultations will feature advice on what to expect from the regulatory
review process and point participants to resources for managing their particular
challenges. Conversations will be centered on where and how to interact with
the FDA around various points of interest (e.g. biomarker validation, data collection
guidelines, IND/NDA tracking, clinical trial protocols, communication with industry).
- Mary Dwight - Vice President of Government Affairs, Cystic Fibrosis Foundation
- Michael Werner, J.D. - Partner, Holland & Knight
|
